<DOC>
	<DOC>NCT01842269</DOC>
	<brief_summary>Efficacy and Safety of My-Rept速 Tablet(Mycophenolate Mofetil 500mg/Tab.) versus My-Rept速 Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination with Tacrolimus in Kidney Transplant Patients</brief_summary>
	<brief_title>Evaluate the Efficacy and Safety of My-Rept速 Tablet vs. My-Rept速 Capsule in Combination With Tacrolimus in Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1. Age 20 years or older. 2. Patient who receive primary or secondary kidney transplantation from living or braindead donor . 3. Patient who receive age 20 years or older donor. 4. Willing and able to provide written informed consent. 1. Cold Ischemia Time &gt; 30 hours. 2. Patient who receive HLAidentical donor. 3. Patient with dual kidney transplantation recipient or have history of other organ transplantation in past or current. 4. Patient who receive extrarenal solid organ or bone marrow stem cell transplantation. 5. Patient who receive kidney transplantation from nonheart beating cadaveric donor(organ donor after cardiac death 6. Patient who receive kidney transplantation from ABO blood type mismatching donor or lymphocyte cross matching (LCM) positive donor. 7. Patient with cancer within 5 years, except cured skin cancer patient(Squamous cell or basal cell carcinoma) 8. Positive in serology test(HIV, HBsAg, HCV) in recipients and/or donor. 9. Patient with Severe gastrointestinal disease in screening period by investigator's decision. 10. Patient with systemic severe infection requiring treatment (able to transplantation after completely disappear or is controlled infection) 11. Liver cirrhosis, clinically significant portal hypertension or other moderate to severe liver disease. 12. Defined by the following laboratory parameters before screening period 1. One of liver function test(AST, ALT, ALP, Total Bilirubin)results increased more than 3 times upper limit of normal range 2. WBC &lt;2,500/mm3, Platelet &lt;75,000/mm3 13. Acute (within 4 weeks) or chronic(need to treatments) allergic/hypersensitivity reaction in the history of Investigational drugs (ex, mycophenolate acid or tacrolimus, etc.) or additives. 14. Administration of other Investigational drugs and/or immunosuppressants within 28days before screening period (except allowed immunosuppressants in protocol) 15. Women in pregnant or breastfeeding or don't using adequate contraception. 16. Patient has conversation impairment because alcohol or drugs addiction history within 6months or mental illness, etc. 17. In investigator's judgment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>MMF</keyword>
</DOC>